If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
184
results.
Updated on
22/10/2026 [11:17:00]
Results 150 to 175 of 184
Absstract of: CN122648562A
The invention provides an application of a preparation for auxiliary diagnosis of Parkinson's disease or assessment of Parkinson's disease risk in preparation of a diagnostic product, and the preparation detects the expression level of TMEM175 in a biological sample so as to carry out auxiliary diagnosis on illness or illness risk of Parkinson's disease. The application has the following advantages: the TMEM175 serum protein level and the SNP rs56039006 regulated by the TMEM175 serum protein level are associated with clinical diagnosis and risk prediction of PD, and a new molecular basis is provided for early-stage, non-invasive or minimally-invasive diagnosis of PD; it is clear that TMEM175 is a key regulatory factor in the PD pathological process, and a brand-new target is provided for developing a disease modification therapy; meanwhile, a complete molecular mechanism is clarified, and a practical screening model is established.
Absstract of: CN122643307A
The invention provides application of hyodeoxycholic acid in preparation of a medicine with a neuroprotective effect. According to the application of the hyodeoxycholic acid in preparation of the medicine for treating the neurodegenerative diseases, the hyodeoxycholic acid has a neuroprotective effect in cells and animal models of the Alzheimer's disease and the Parkinson's disease, and compared with the cell damage models of the Alzheimer's disease and the Parkinson's disease, the hyodeoxycholic acid has the neuroprotective effect. The hyodeoxycholic acid administration can improve the cell viability, and compared with animal models of Alzheimer's disease and Parkinson's disease, the hyodeoxycholic acid can improve the behavior and learning function of mice and reduce neuron damage, so that the hyodeoxycholic acid can be used as a neuroprotective drug for preventing or treating neurodegenerative diseases, and has a good application prospect. The invention has the prospect of developing bile acid medicines for preventing or treating neurodegenerative diseases, and has important clinical significance and commercial value.
Absstract of: CN122643343A
The invention belongs to the technical field of natural product extraction and medicinal development, and discloses a preparation method and application of drynaria fortunei total flavone in order to solve the technical problem that drynaria fortunei leaf total flavone extraction and drynaria fortunei flavone yield and biological activity are difficult to consider at the same time. A double-index comprehensive evaluation system of the total flavone yield and the acetylcholin esterase inhibitory activity is established, and the screening optimization of the extraction and purification process is guided by taking a comprehensive score value greater than or equal to 80 as a process feasible standard and greater than or equal to 95 as an optimal end point basis. Based on the system, key factors are screened through Plackett-Burman design, and optimal extraction conditions are determined through orthogonal test optimization; and then optimizing macroporous adsorption resin for purification and enrichment. According to the drynaria fortunei total flavonoids and the preparation method, the yield, the purity and the biological activity can be synergistically improved, the drynaria fortunei total flavonoids can be used for preparing anti-Alzheimer disease related products, the process is stable and reliable, and the drynaria fortunei total flavonoids are suitable for high-value development and industrial application of drynaria fortunei leaf resources.
Absstract of: CN122647562A
The invention discloses a targeted MST1 and p53 combined polypeptide and application thereof in treatment of Alzheimer's disease, and relates to the field of biological medicine. The polypeptide provided by the embodiment of the invention can block a neurodegenerative process from the upstream by targeting MST1 kinase, not only has a direct neuroprotective effect, but also can improve synaptic plasticity, and is expected to realize substantial intervention on a disease process, not limited to relieving symptoms. As a polypeptide drug, the polypeptide has the advantages of small molecular weight, better potential tissue penetrability, lower immunogenicity and better safety and tolerance. The polypeptide can more effectively intervene in the AD disease progress, improves cognitive impairment and memory dysfunction of patients, and provides a new way for AD treatment.
Absstract of: CN122647396A
The invention relates to the technical field of natural products, and provides a pimarane diterpenoid alkaloid compound as well as a preparation method and application thereof. The chemical structural formula of the pimarane diterpenoid alkaloid compound is shown as any one of formulas I-VI, and the pimarane diterpenoid alkaloid compound is applied to preparation of drugs for preventing and/or treating Alzheimer's disease. Six novel pimarane diterpenoid alkaloid compounds are separated from the traditional Chinese medicine Dendrobium fimbriatum, and the chemical substance basis of Dendrobium fimbriatum is expanded. In-vitro experiments prove that the pimarane diterpenoid alkaloid compound has good acetylcholin esterase inhibitory activity, can be used for preparing neuroprotective drugs, especially for preventing and/or treating Alzheimer's disease, and provides alternative compounds for developing new neuroprotective drugs.
Absstract of: CN122662848A
The present disclosure provides treatment of Parkinson's disease (PD) comprising administering acetylleucine, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
Absstract of: CN122643305A
The invention relates to application of certain compounds, or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs, tautomers, isotope compounds, metabolites or prodrugs of the compounds, or corresponding pharmaceutical compositions of the compounds in preparation of drugs for preventing or treating alpha-synuclein related diseases. The invention further discloses a method for preparing the animal model for expressing the humanized alpha-synuclein and a method for preparing the humanized Parkinson's disease animal model.
Absstract of: CN122643463A
The invention discloses an NAD < + >-related nano-drug brain-targeted delivery system and a preparation method and application thereof.The delivery system is composed of a core containing NAD < + >-related active ingredients and a carrier shell with the surface modified with a brain-targeted ligand, and the NAD < + >-related active ingredients are compounded and coordinated to achieve high drug loading and stable encapsulation; through joint modification of multiple types of brain-targeted ligands, the delivery system has blood-brain barrier-crossing transport and intracerebral cell localization capabilities. NAD + supplement and a GLUT1/RVG double-ligand brain targeting strategy are combined, a safe, high-drug-loading and high-stability NAD + related nano-drug system is constructed, the NAD (H) content of brain tissue can be increased, the mitochondrial function can be improved, oxidative stress and neuroinflammation can be reduced, astrocyte senescence phenotype can be reversed or relieved, and the NAD + related nano-drug system can be used for treating astrocyte senescence. And a new drug delivery strategy is provided for Parkinson's disease and senescence-related neurodegenerative diseases.
Absstract of: US20260250715A1
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
Absstract of: US20260248855A1
Use of a transforming growth factor beta 1 (TGF-β1)-overexpressing olfactory mucosa mesenchymal stem cell (OM-MSC) in preparation of a drug for preventing and/or treating Parkinson's disease (PD) is provided, belonging to the technical field of drug preparation. The TGF-β1-overexpressing OM-MSCs can be used to better conduct a neural repair treatment of the PD. By verifying effects of the TGF-β1-overexpressing OM-MSCs in a PD cell model and a PD animal model, it is proved that the TGF-β1-overexpressing OM-MSCs do have a therapeutic effect on PD.
Absstract of: US20260248877A1
0000 The present invention provides inhibitory peptides for use in the diagnostic and/or treatment of tauopathies, in particular Alzheimer's Disease and Pick's Disease. The inhibitory peptides comprise a hexapeptide sequence that specifically inhibits interactions of the PHF6 sequence within pathological Tau protein.
Absstract of: US20260248883A1
0000 Disclosed is a pharmaceutical composition for preventing or treating a brain disease, containing as an active ingredient an ErbB3-binding protein 1 (EBP1) protein or a polynucleotide sequence encoding the EBP1 protein, wherein an EBP1 N84A/N204A protein, which is an EBP1 mutant in an asparagine endopeptidase (AEP)-uncleavable form, and a polynucleotide encoding the same can reduce amyloid beta production and enhance cognitive function in the early stages of Alzheimer's disease, and thus the composition can be advantageously used as a therapeutic agent for brain diseases including sporadic Alzheimer's disease.
Absstract of: US20260248941A1
0000 Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
Absstract of: US20260250256A1
0000 Disclosed are compounds of Formulas (I), (Ia), (Ib), (II), (IIa), (III), (IIIa), and (IIIb), as well as pharmaceutical compositions thereof. The compounds can be used to improve proteostasis and enhance clearance of protein accumulation events by positively modulating the autophagy-lysosomal pathway, including augmenting the activity of cathepsin enzymes, and/or to treat neurological diseases, disorders and conditions, such as, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, mild cognitive impairment, frontotemporal dementia, amyotrophic lateral sclerosis, Lewy body dementias, chronic traumatic encephalopathy, traumatic brain injury, and α-synucleinopathies.
Absstract of: US20260250396A1
Provided herein are therapies involving the use of antibodies that bind to Gal-3. Such therapies can include, but are not limited to, disorders such as Alzheimer's disease. Such therapies can also include treatments focused on increasing a subject's test scores under a variety of metrics.
Absstract of: WO2026178556A1
Among other things, the present disclosure provides oligonucleotides, compositions, and methods useful for targeting HTT. In some embodiments, provided oligonucleotides comprise nucleobase modifications, sugar modifications, internucleotidic linkage modifications and/or patterns thereof, and have improved properties and activities. In some embodiments, the present disclosure provides oligonucleotides, compositions and methods for reducing HTT levels. In some embodiments, the present disclosure provides oligonucleotides, compositions and methods for treating conditions, disorders or diseases such as Huntington's disease.
Absstract of: WO2026178437A2
The present invention relates to methods for treating, preventing or delaying onset, and alleviating the symptoms of amyotrophic lateral sclerosis (ALS) through nasally or intrathecally administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising dantrolene or a combination of dantrolene and a lithium salt, and a pharmaceutically acceptable carrier. The present invention further relates to methods for treating depression comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising dantrolene or a combination of dantrolene and a lithium salt, and a pharmaceutically acceptable carrier. The present invention additionally relates to methods for treating depression in an Alzheimer's Disease subject comprising administering a pharmaceutical composition comprising dantrolene or a combination of dantrolene and a lithium salt, and a pharmaceutically acceptable carrier.
Absstract of: EP4796178A2
Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
Absstract of: WO2025083630A1
The present invention relates to heteroaromatic compounds of formula (I), or an isotopic form, a stereoisomer, or a pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulators (M4 PAMs). The present invention also relates to pharmaceutical compositions comprising such compounds, chemical processes of preparation of such compounds and use of such compounds in the treatment of psychiatric and/or neurological disorders.
Absstract of: WO2025085704A1
This disclosure relates to vectors, compositions, pharmaceutical compositions, and kits that provide for brain cell-specific expression of reprogramming genes such as the Yamanaka factors Oct4, Sox2, Klf4 and c-Myc (OSKM). Also provided are methods and uses comprising the same for treating Alzheimer' s disease and progeria through brain cell-specific expression of reprogramming genes such as OSKM.
Absstract of: CN122624459A
The invention discloses an application of chrysolic acid in treatment of Alzheimer's disease. SCA intervention can significantly improve cognitive memory dysfunction and protect brain tissue structural integrity; the SCA can reduce abnormal deposition of Abeta in the brain, reduce the number and the distribution range of Abeta positive plaques and relieve AD core pathological damage; the SCA can improve pathological injury and cognitive dysfunction of a central nervous system by regulating intestinal microecology. The invention has important scientific significance and clinical transformation value for developing a novel safe and efficient Alzheimer disease intervention method.
Absstract of: CN122628119A
The invention discloses a polymorphic substance of asiaticoside as well as a preparation method and medical application of the polymorphic substance. The invention proves that the asiaticoside has a polymorphic phenomenon for the first time, and provides various crystal forms of the asiaticoside suitable for being used as a raw material medicine, and the crystal forms can be used for developing an asiaticoside preparation with controllable quality. The invention provides a simple, easy and environment-friendly preparation method of the polymorphic substance of asiaticoside, and the preparation method is suitable for large-scale production. The invention relates to a polymorphic substance of asiaticoside or a pharmaceutical composition containing a crystal substance of asiaticoside. The pharmaceutical composition can be used for preventing and treating the following diseases: type I interferon disease, peptic ulcer, Parkinson's disease, ulcerative colitis, systemic sclerosis, hepatic fibrosis, pulmonary fibrosis, renal fibrosis, Alzheimer's disease, depression, diabetic foot ulcer and difficult-to-heal wounds.
Absstract of: CN122628971A
The invention discloses a rhizoma acori graminei-sourced extracellular nano-vesicle and application thereof, and belongs to the technical field of biological medicines. The extracellular nano-vesicle is extracted from rhizoma acori graminei, has the capabilities of resisting neuroinflammation and penetrating a blood brain barrier, is loaded with an siRNA drug for treating the Alzheimer's disease, can efficiently deliver siRNA to a brain lesion site, improves the concentration of the drug in the brain, and plays a role in synergistic interaction. Compared with a synthetic nano-carrier, the nano-carrier is more suitable for long-term administration, and provides advantages for chronic treatment of Alzheimer's disease. The extracellular nano-vesicle can load siRNA aiming at different pathogenic genes, realizes simultaneous intervention on multiple pathogenic links of the Alzheimer's disease, has the potential of multi-target collaborative treatment, and is expected to more effectively prevent the progress of the Alzheimer's disease.
Absstract of: CN122628226A
The invention discloses fig acidic polysaccharide for promoting removal of beta-amyloid protein, a method and application. The fig acidic polysaccharide is composed of seven monosaccharides, including rhamnose, arabinose, galactose, glucose, xylose, mannose and galacturonic acid. According to the method, fig fruits are used as raw materials, an ultrasonic-assisted deep eutectic solvent technology is adopted for extracting fig crude polysaccharide FCPs, then fig polysaccharide is subjected to column chromatography separation, and a uniform acidic polysaccharide component named as FCP-2P is obtained. The acidic polysaccharide FCP-2P can be used as a functional component to be applied to functional food or medicine related fields, and is used for promoting the removal of beta-amyloid protein so as to prevent or treat Alzheimer's disease (AD). According to the invention, the medicinal value and the application prospect of the fig are widened, and a new choice is provided for prevention and adjuvant therapy of AD (Alzheimer's disease).
Nº publicación: CN122628037A 25/08/2026
Applicant:
INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES
\u4E2D\u56FD\u533B\u5B66\u79D1\u5B66\u9662\u836F\u7269\u7814\u7A76\u6240
Absstract of: CN122628037A
The invention discloses an eutectic substance formed by combining puerarin (English name: Puerarin) and tyrosine (English name: Tyrosine) through a non-covalent bond as well as a preparation method and application of the eutectic substance. Specifically, the invention discloses an eutectic substance formed by puerarin and tyrosine, the molecular formula of the eutectic substance is C21H20O9. C14H19NO5, and the molecular formula of the eutectic substance is C21H20O9. C14H19NO5. The invention discloses a preparation method of puerarin and tyrosine eutectic. The puerarin and tyrosine eutectic is applied to preparation of drugs with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting hypertension, reducing blood sugar, resisting inflammation, relieving fever and easing pain, resisting Alzheimer's disease, resisting osteoporosis and the like.
BOPI
Electronic site
